Achieving systemic delivery of oncolytic viruses

References

• Side effects of chemotherapy. Cancer.Net. [Internet]. [cited 2019 Feb 26]. Available from. https://www.cancer.net/navigating-cancer-care/how-cancer-treated/chemotherapy/side-effects-chemotherapy
   Google Scholar
• Firdos M, Ziaddin DLB. Viral Therapy of Cancer. In: Harrington VIle P, editor. Chapter 9: oncolytic vaccinia. John Wiley & Sons, Ltd; 2008;151–169.
   Google Scholar
• Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering . Mol Ther. 2007 Apr;15:651–659. Available from http://linkinghub.elsevier.com/retrieve/pii/S1525001616313314
   PubMed Web of Science ®Google Scholar
• Martuza RL, Malick A, Markert JM, et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 80-. 1991;252:854–856. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1851332
   PubMed Web of Science ®Google Scholar
• Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30:658–670. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22781695
   PubMed Web of Science ®Google Scholar
• Lawler SE, Speranza M-C, Cho C-F, et al. Oncolytic viruses in cancer treatment. JAMA Oncol. 2017;3:841. Available from: http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.2064
   PubMed Web of Science ®Google Scholar
• Russell SJ, Peng K-W. Oncolytic Virotherapy: A Contest between Apples and Oranges. Mol Ther. 2017;25:1107–1116. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28392162
   PubMed Web of Science ®Google Scholar
• Cattaneo R, Miest T, Shashkova EV, et al. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol. 2008;6:529–540. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947522/
   PubMed Web of Science ®Google Scholar
• Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997;3:639–645. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9176490
   PubMed Web of Science ®Google Scholar
• Bell JC, Stojdl DF, Lichty B, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 2000;6:821–825. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10888934
   Web of Science ®Google Scholar
• Hermiston T. Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J Clin Invest. 2000;105:1169–1172. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10791988
   PubMed Web of Science ®Google Scholar
• Yurchenko KS, Zhou P, Kovner AV, et al. Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model. Ulasov Ieditor. PLoS One.2018;13:e0195425. Available from: https://dx.plos.org/10.1371/journal.pone.0195425
   PubMed Web of Science ®Google Scholar
• Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2:277–288.
   PubMed Web of Science ®Google Scholar
• Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000;7:867–874. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10845725
   PubMed Web of Science ®Google Scholar
• Markert JM, Liechty PG, Wang W, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther. 2009;17:199–207. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18957964
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Hingorani M, Tanay MA, et al. Phase I/II study of oncolytic hsvgm-csf in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res. 2010;16:4005–4015. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20670951
   PubMed Web of Science ®Google Scholar
• Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor- encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27:5763–5771. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19884534
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kim DW, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010;17:718–730. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19915919
   PubMed Web of Science ®Google Scholar
• Conry RM, Khazaeli MB, Saleh MN, et al. Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin Cancer Res. 1999;5:2330–2337. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10499601
   PubMed Web of Science ®Google Scholar
• Mastrangelo MJ, Maguire HC, Eisenlohr LC, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 1999;6:409–422. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10505851
   PubMed Web of Science ®Google Scholar
• B-H P, Hwang T, T-C L, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008;9:533–542. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18495536
   PubMed Web of Science ®Google Scholar
• Hwang T-H, Moon A, Burke J, et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther. 2011;19:1913–1922. Available from: http://dx.doi.org/10.1038/mt.2011.132/nature06264
   PubMed Web of Science ®Google Scholar
• Zeh HJ, Downs-Canner S, McCart JA, et al. First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity. Mol Ther. 2015;23:202–214.
   PubMed Web of Science ®Google Scholar
• Cripe TP, Ngo MC, Geller JI, et al. Phase 1 study of intratumoral pexa-vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther. 2015;23:602–608. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1525001616300727
   PubMed Web of Science ®Google Scholar
• Mansfield D, Kyula J, Rosenfelder N, et al. Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer. Gene Ther. 2016;23:357–368.
   PubMed Web of Science ®Google Scholar
• Breitbach CJ, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477:99–102. Available from: http://dx.doi.org/10.1038/nature10358
   PubMed Web of Science ®Google Scholar
• Liikanen I, Ahtiainen L, Hirvinen ML, et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther. 2013;21:1212–1223. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23546299
   PubMed Web of Science ®Google Scholar
• Morse MA, Chaudhry A, Gabitzsch ES, et al. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol Immunother. 2013;62:1293–1301. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23624851
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Nemunaitis J. Head and neck cancer: response to p53-based therapeutics. Eisele DW, editor. Head Neck. . 2011;33:131–134. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20222046
   PubMed Web of Science ®Google Scholar
• Chang J, Zhao X, Wu X, et al. A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biol Ther. 2009;8:676–682. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19242097
   PubMed Web of Science ®Google Scholar
• Li J-L, Liu H-L, Zhang X-R, et al. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Ther. 2009;16:376–382. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19092859
   PubMed Web of Science ®Google Scholar
• Barton KN, Paielli D, Zhang Y, et al. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and adp gene demonstrates greater efficacy without increased toxicity. Mol Ther. 2006;13:347–356. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16290236
   PubMed Web of Science ®Google Scholar
• Reid TR, Freeman S, Post L, et al. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther. 2005;12:673–681. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15803147
   PubMed Web of Science ®Google Scholar
• Morley S, MacDonald G, Kirn D, et al. The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin Cancer Res.. 2004;10:4357–4362. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15240522
   PubMed Web of Science ®Google Scholar
• Hecht JR, Bedford R, Abbruzzese JL, et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res.. 2003;9:555–561. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12576418
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. 2001;8:746–759. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11420638
   PubMed Web of Science ®Google Scholar
• Sheridan C. First Oncolytic virus edges towards approval in surprise vote. Nat Biotechnol. [Internet]. 2015;33:569–570. Available from: http://www.nature.com/doifinder/10.1038/nbt0615-569
   PubMed Web of Science ®Google Scholar
• Garber K. China approves world’s first oncolytic virus therapy for cancer treatment. JNCI J Natl Cancer Inst. [Internet]. 2006 [cited 2019 Jan 23];98:298–300. Available from: http://academic.oup.com/jnci/article/98/5/298/2522047/China-Approves-Worlds-First-Oncolytic-Virus
   Web of Science ®Google Scholar
• Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic. immune stimulating, and anti-tumour properties. Gene Ther; 2003;10:292–303.
   Web of Science ®Google Scholar
• Bommareddy PK, Patel A, Hossain S, et al. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. Am J Clin Dermatol. 2017;18:1–15. Available from: http://link.springer.com/10.1007/s40257-016-0238-9
   PubMed Web of Science ®Google Scholar
• Rehman H, Silk AW, Kane MP, et al. Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer. 2016;4:53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27660707
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015.
   PubMed Web of Science ®Google Scholar
• Skelding KA, Barry RD, Shafren DR. Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride. Invest New Drugs. 2012;30:568–581. Available from: http://link.springer.com/10.1007/s10637-010-9614-0
   PubMed Web of Science ®Google Scholar
• Andtbacka RHI, Curti BD, Kaufman H, et al. CALM study: A phase II study of an intratumorally delivered oncolytic immunotherapeutic agent, coxsackievirus A21, in patients with stage IIIc and stage IV malignant melanoma. J Clin Oncol. 2014;32:3031. Available from: http://ascopubs.org/doi/10.1200/jco.2014.32.15_suppl.3031
   Web of Science ®Google Scholar
• Bernstein V, Ellard SL, Dent SF, et al. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. Breast Cancer Res Treat. 2018;167:485–493. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29027598
   PubMed Web of Science ®Google Scholar
• Samson A, Scott KJ, Taggart D, et al. Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci Transl Med. 2018;10:eaam7577. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29298869
   PubMed Web of Science ®Google Scholar
• Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19:329–336.
   PubMed Web of Science ®Google Scholar
• Jennerex TSA. Jennerex and transgene present positive clinical data from phase 2 trial of JX594/TG6006 in sorafenib-refractory liver cancer patients [Internet]. [cited 2017 Aug 6]. Available from: https://www.transgene.fr/wp-content/uploads/PR/214_en.pdf.
   Google Scholar
• Downs-Canner S, Guo ZS, Ravindranathan R, et al. Phase 1 study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancers. Mol Ther. 2016;24:1492–1501. [Internet]. Available from: http://www.nature.com/mt/journal/vaop/ncurrent/full/mt2016101a.html
   PubMed Web of Science ®Google Scholar
• Evgin L, Acuna SA, Tanese de Souza C, et al. Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. Mol Ther. 2015;23:1066–1076. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25807289
   PubMed Web of Science ®Google Scholar
• Fisher KD, Stallwood Y, Green NK, et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 2001;8:341–348.
   PubMed Web of Science ®Google Scholar
• Miller A, Suksanpaisan L, Naik S, et al. Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy. Mol Ther Oncolytics. 2014;1:14005. [Internet]. Available from: http://dx.doi.org/10.1038/mto.2014.5
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10.
   Web of Science ®Google Scholar
• Bourgeois-Daigneault M-C, Roy DG, Aitken AS, et al. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci Transl Med. 2018;10:eaao1641. Available from http://stm.sciencemag.org/
   PubMed Web of Science ®Google Scholar
• Kuhn I, Harden P, Bauzon M, et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. Jin D-Y, editor. PLoS One. 2008;3:e2409. Available from: https://dx.plos.org/10.1371/journal.pone.0002409
   PubMed Web of Science ®Google Scholar
• Bauzon M, Hermiston TW. Oncolytic viruses: the power of directed evolution. Adv Virol. 2012;2012:586389. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22312363
   PubMedGoogle Scholar
• Patel MR, Kratzke RA. Genetic engineering of oncolytic viruses for cancer therapy. transl. Gene Ther to Clin. 2015;261–279. Available from: https://www.sciencedirect.com/science/article/pii/B9780128005637000178
   Google Scholar
• Leber MF, Bossow S, Leonard VHJ, et al. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. Mol Ther. 2011;19:1097–1106.
   PubMed Web of Science ®Google Scholar
• Hikichi M, Kidokoro M, Haraguchi T, et al. MicroRNA regulation of glycoprotein B5R in oncolytic vaccinia virus reduces viral pathogenicity without impairing its antitumor efficacy. Mol Ther. 2011;19:1107–1115.
   PubMed Web of Science ®Google Scholar
• Lee CYF, Rennie PS, Jia WWG. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Clin Cancer Res. 2009;15:5126–5135.
   Web of Science ®Google Scholar
• Edge RE, Falls TJ, Brown CW, et al. A let-7 microRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther. 2008;16:1437–1443.
   PubMed Web of Science ®Google Scholar
• Kelly EJ, Hadac EM, Greiner S, et al. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med. 2008;14:1278–1283.
   Web of Science ®Google Scholar
• Ylosmaki E, Martikainen M, Hinkkanen A, et al. Attenuation of semliki forest virus neurovirulence by microRNA-mediated detargeting. J Virol. 2013;87:335–344. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23077310
   PubMed Web of Science ®Google Scholar
• Delwar ZM, Liu G, Kuo Y, et al. Tumour-specific triple-regulated oncolytic herpes virus to target glioma. Oncotarget. 2016;7:28658–28669. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27070093
   PubMedGoogle Scholar
• Verheije MH, Rottier PJM. Retargeting of viruses to generate oncolytic agents. Adv Virol. 2012;2012:798526. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22312365
   PubMedGoogle Scholar
• Petrovic B, Gianni T, Gatta V, et al. Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins. Palese P, editor. PLOS Pathog.2017;13:e1006352. Available from: https://dx.plos.org/10.1371/journal.ppat.1006352
   PubMed Web of Science ®Google Scholar
• Nakamura T, Peng K-W, Harvey M, et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol. 2005;23:209–214. Available from: http://www.nature.com/articles/nbt1060
   PubMed Web of Science ®Google Scholar
• Kreppel F, Gackowski J, Schmidt E, et al. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol Ther. 2005;12:107–117. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15963926
   PubMed Web of Science ®Google Scholar
• Krutzke L, Prill JM, Engler T, et al. Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: preventing vector clearance and preserving infectivity. J Control Release. 2016;235:379–392. Available from: https://www.sciencedirect.com/science/article/pii/S016836591630387X?via%3Dihub
   PubMed Web of Science ®Google Scholar
• Reichard KW, Lorence RM, Cascino CJ, et al. Newcastle disease virus selectively kills human tumor cells. J Surg Res.1992;52:448–453. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1619912
   PubMed Web of Science ®Google Scholar
• Krishnamurthy S, Takimoto T, Scroggs RA, et al. Differentially regulated interferon response determines the outcome of newcastle disease virus infection in normal and tumor cell lines. J Virol. 2006;80:5145–5155. Available from: http://jvi.asm.org/
   PubMed Web of Science ®Google Scholar
• Freeman AI, Zakay-Rones Z, Gomori JM, et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther. 2006;13:221–228. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1525001605015704
   PubMed Web of Science ®Google Scholar
• Laurie SA, Bell JC, Atkins HL, et al. A Phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res. 2006;12:2555–2562. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16638865
   PubMed Web of Science ®Google Scholar
• Pecora AL, Rizvi N, Cohen GI, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol. 2002;20:2251–2266. Available from: http://ascopubs.org/doi/10.1200/JCO.2002.08.042
   PubMed Web of Science ®Google Scholar
• Kirn DH, Wang Y, Liang W, et al. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res. 2008;68:2071–2075. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18381410
   PubMed Web of Science ®Google Scholar
• Chen H, Lin Yuan WSZWDL, Chen H, et al. Biocompatible polymer materials: role of protein-surface interactions. Prog Polym Sci. 2008;33:1059–1087.
   Web of Science ®Google Scholar
• O’Riordan CR, Lachapelle A, Delgado C, et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther. 1999;10:1349–1358. Available from: http://www.liebertpub.com/doi/10.1089/10430349950018021
   PubMed Web of Science ®Google Scholar
• Green NK, Morrison J, Hale S, et al. Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. J Gene Med. 2008;10:280–289. Available from: http://doi.wiley.com/10.1002/jgm.1121
   PubMed Web of Science ®Google Scholar
• Morrison J, Briggs SS, Green N, et al. Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Mol Ther. 2008;16:244–251. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18071336
   PubMed Web of Science ®Google Scholar
• Stevenson M, Hale ABH, Hale SJ, et al. Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via α6-integrins. Cancer Gene Ther. 2007;14:335–345. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17235355
   PubMed Web of Science ®Google Scholar
• Croyle MA, Chirmule N, Zhang Y, et al. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther. 2002;13:1887–1900.
   PubMed Web of Science ®Google Scholar
• Wonganan P, Croyle MA. PEGylated Adenoviruses: from Mice to Monkeys. Viruses. 2010;2:468–502. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21994645
   PubMed Web of Science ®Google Scholar
• Croyle MA, Chirmule N, Zhang Y, et al. “Stealth” adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol. 2001;75:4792–4801.
   PubMed Web of Science ®Google Scholar
• Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol. 2000;81:2605–2609.
   PubMed Web of Science ®Google Scholar
• Mok H, Palmer DJ, Ng P, et al. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther. 2005;11:66–79. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1525001604014637
   PubMed Web of Science ®Google Scholar
• Nguyen TV, Heller GJ, Barry MAME, et al. Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers. Mol Ther - Oncolytics. 2016;3:15021. Available from: https://www.sciencedirect.com/science/article/pii/S2372770516300298
   PubMed Web of Science ®Google Scholar
• Green NK, Herbert CW, Hale SJ, et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 2004;11:1256–1263. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15215884
   PubMed Web of Science ®Google Scholar
• Fisher KD, Green NK, Hale A, et al. Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. J Drug Target. 2007;15:546–551. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17671901
   PubMed Web of Science ®Google Scholar
• Green NK, Hale A, Cawood R, et al. Tropism ablation and stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves virotherapy of cancer. Nanomedicine. 2012;7:1683–1695. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22709345%5Cnhttp://www.futuremedicine.com/doi/abs/10.2217/nnm.12.50
   PubMed Web of Science ®Google Scholar
• Prill JM, Šubr V, Pasquarelli N, et al. Traceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivo. Hong S-S, editor. PLoS One. 2014;9:e82716. Available from: https://dx.plos.org/10.1371/journal.pone.0082716
   PubMed Web of Science ®Google Scholar
• Carlisle R, Choi J, Bazan-Peregrino M, et al. Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasound. J Natl Cancer Inst. 2013 ;105:1701–1710. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24168971
   PubMed Web of Science ®Google Scholar
• Bonsted A, Engesaeter BO, Hogset A, et al. Photochemically enhanced transduction of polymer-complexed adenovirus targeted to the epidermal growth factor receptor. J Gene Med. 2006;8:286–297. Available from:
   PubMed Web of Science ®Google Scholar
• Kasman LM, Barua S, Lu P, et al. Polymer-enhanced adenoviral transduction of CAR-negative bladder cancer cells. Mol Pharm. American Chemical Society; 2009; 6: 1612–1619. Available from: http://pubs.acs.org/doi/abs/10.1021/mp9000958
   PubMed Web of Science ®Google Scholar
• Jiang ZK, Koh SBS, Sato M, et al. Engineering polypeptide coatings to augment gene transduction and in vivo stability of adenoviruses. J Control Release. 2013;166:75–85. Available from: https://www.sciencedirect.com/science/article/pii/S0168365912008334
   PubMed Web of Science ®Google Scholar
• Kim J, Li Y, Kim SW, et al. Therapeutic efficacy of a systemically delivered oncolytic adenovirus - Biodegradable polymer complex. Biomaterials. 2013;34:4622–4631. Available from: https://www.sciencedirect.com/science/article/pii/S014296121300286X
   PubMed Web of Science ®Google Scholar
• Choi J-W, Jung S-J, Kasala D, et al. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis. J Control Release. 2015;205:134–143. Available from: https://www.sciencedirect.com/science/article/pii/S0168365915000061
   PubMed Web of Science ®Google Scholar
• Choi JW, Kim J, Bui QN, et al. Tuning surface charge and pegylation of biocompatible polymers for efficient delivery of nucleic acid or adenoviral vector. Bioconjug Chem. 2015;26:1818–1829. Available from: http://pubs.acs.org/doi/10.1021/acs.bioconjchem.5b00357
   PubMed Web of Science ®Google Scholar
• Fasbender A, Zabner J, Chillón M, et al. Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J Biol Chem. 1997;272:6479–6489. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9045673
   PubMed Web of Science ®Google Scholar
• Kwon O-J, Kang E, Choi J-W, et al. Therapeutic targeting of chitosan–PEG–folate-complexed oncolytic adenovirus for active and systemic cancer gene therapy. J Control Release. 2013;169:257–265. Available from: https://www.sciencedirect.com/science/article/pii/S0168365913001739
   PubMed Web of Science ®Google Scholar
• Kim J, Nam HY, Choi JW, et al. Efficient lung orthotopic tumor-growth suppression of oncolytic adenovirus complexed with RGD-targeted bioreducible polymer. Gene Ther. 2014;21:476–483. Available from: http://www.nature.com/articles/gt201418
   PubMed Web of Science ®Google Scholar
• Nosaki K, Hamada K, Takashima Y, et al. A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity. Mol Ther - Oncolytics. 2016;3:16022. Available from: http://www.nature.com/articles/mto201622
   PubMed Web of Science ®Google Scholar
• Rojas JJ, Sampath P, Bonilla B, et al. Manipulating TLR signaling increases the anti-tumor T cell response induced by viral cancer therapies. Cell Rep. 2016;15:264–273.
   PubMed Web of Science ®Google Scholar
• Grundy M, Coussios C, Carlisle R. Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer. Expert Opin Drug Deliv. 2016;13:999–1013. Available from: http://www.tandfonline.com/doi/full/10.1517/17425247.2016.1167036
   PubMed Web of Science ®Google Scholar
• Romanczuk H, Galer CE, Zabner J, et al. Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice. Hum Gene Ther. 1999;10:2615–2626.
   Web of Science ®Google Scholar
• Campos SK, Barry MA. Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Virology. 2006;349:453–462. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0042682206000420
   PubMed Web of Science ®Google Scholar
• Virgin HW. Pathogenesis of viral infection. In: Fields BN, Knipe DM, Howley PM, editors. Fields’ Virology. Philadelphia: Wolters kluwer/Lippincott Williams & Wilkins; 2007.
   Google Scholar
• Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006 ;6:583–592. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16862189
   PubMed Web of Science ®Google Scholar
• Nichols JW, Bae YH. Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today. 2012 ;7:606–618. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23243460
   PubMed Web of Science ®Google Scholar
• Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release. 2001;74:47–61.
   PubMed Web of Science ®Google Scholar
• Baker JHE, Lindquist KE, Huxham LA, et al. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res. 2008;14:2171–2179. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18381959
   PubMed Web of Science ®Google Scholar
• Tailor TD, Hanna G, Yarmolenko PS, et al. Effect of Pazopanib on tumor microenvironment and liposome delivery. Mol Cancer Ther. 2010;9:1798–1808. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20515941
   PubMed Web of Science ®Google Scholar
• Primeau AJ, Rendon A, Hedley D, et al. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res. 2005;11:8782–8788. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16361566
   PubMed Web of Science ®Google Scholar
• Goel S, Wong AH-K, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease Cold Spring Harb. Perspect Med. 2012;2:a006486. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22393532
   Google Scholar
• Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005;69:11–16.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789–799.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473:298–307.
   PubMed Web of Science ®Google Scholar
• Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650–1659.
   PubMed Web of Science ®Google Scholar
• Jain RK. Taming vessels to treat cancer. Sci Am. 2008;298:56–63.
   PubMed Web of Science ®Google Scholar
• Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncol. willist. Park. 2005;19:7–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15934498
   Google Scholar
• Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841–844.
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–1544.
   PubMed Web of Science ®Google Scholar
• Lee CG, Heijn M, Di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000;60:5565–5570.
   Web of Science ®Google Scholar
• Wildiers H, Guetens G, De Boeck G, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer. 2003;88:1979–1986.
   PubMed Web of Science ®Google Scholar
• Tong RT, Boucher Y, Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64:3731–3736.
   Web of Science ®Google Scholar
• Dickson PV, Hamner JB, Sims TL, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res. 2007;13:3942–3950.
   PubMed Web of Science ®Google Scholar
• Kim M, Nitschké M, Sennino B, et al. Amplification of oncolytic vaccinia virus widespread tumor cell killing by sunitinib through multiple mechanisms. Cancer Res.2018;78:922–937. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29259007
   PubMed Web of Science ®Google Scholar
• Kurozumi K, Hardcastle J, Thakur R, et al. Effect of Tumor Microenvironment Modulation on the Efficacy of Oncolytic Virus Therapy. JNCI J Natl Cancer Inst.2007;99:1768–1781. Available from: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djm229
   Web of Science ®Google Scholar
• Breitbach CJ, Arulanandam R, De Silva N, et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res. 2013;73:1265–1275. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23393196
   PubMed Web of Science ®Google Scholar
• Hou W, Chen H, Rojas J, et al. Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF. Int J Cancer. 2014;135:1238–1246. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24474587
   PubMed Web of Science ®Google Scholar
• Seki T, Carroll F, Illingworth S, et al. Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway. J Control Release. 2011;156:381–389.
   PubMed Web of Science ®Google Scholar
• Pencavel TD, Wilkinson MJ, Mansfield DC, et al. Isolated limb perfusion with melphalan, tumour necrosis factor-Alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma. Int J Cancer. 2015;136:965–976.
   PubMed Web of Science ®Google Scholar
• Arulanandam R, Batenchuk C, Angarita FA, et al. VEGF-mediated induction of PRD1-BF1/blimp1 expression sensitizes tumor vasculature to oncolytic virus infection. Cancer Cell.2015;28:210–224. Available from: https://www.sciencedirect.com/science/article/pii/S1535610815002196?via%3Dihub
   PubMed Web of Science ®Google Scholar
• Miller A, Nace R, Ayala-Breton CC, et al. Perfusion pressure is a critical determinant of the intratumoral extravasation of oncolytic viruses. Mol Ther. 2016;24:306–317. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26647825
   PubMed Web of Science ®Google Scholar
• Seymour LW, Fisher KD. Under pressure: elevated blood pressure enhances targeting of tumors by oncolytic viruses. Mol Ther. 2016;24:204–205. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26906615
   PubMed Web of Science ®Google Scholar
• Ibsen S, Benchimol M, Simberg D, et al. Nano-biotechnology for biomedical and diagnostic research. In: Zahavy E, Ordentlich A, Yitzhaki S, et al. editors. Dordrecht: Springer Netherlands; 2012. 145–153. Available from: 10.1007/978-94-007-2555-3_14
   Google Scholar
• Lyon PC, Gray MD, Mannaris C, et al. Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial. Lancet Oncol. 2018;19:1027–1039.
   Web of Science ®Google Scholar
• Stride EP, Coussios CC. Cavitation and contrast: the use of bubbles in ultrasound imaging and therapy. Proc Inst Mech Eng Part H J Eng Med. 2010.
   PubMed Web of Science ®Google Scholar
• Arvanitis CD, Bazan-Peregrino M, Rifai B, et al. Cavitation-enhanced extravasation for drug delivery. Ultrasound Med Biol. 2011;37:1838–1852.
   PubMed Web of Science ®Google Scholar
• Rifai B, Arvanitis CD, Bazan-Peregrino M, et al. Cavitation-enhanced delivery of macromolecules into an obstructed vessel. J Acoust Soc Am. 2010;128:310–315. Available from: http://scitation.aip.org/content/asa/journal/jasa/128/5/10.1121/1.3496388
   PubMed Web of Science ®Google Scholar
• Howard CM, Forsberg F, Minimo C, et al. Ultrasound guided site specific gene delivery system using adenoviral vectors and commercial ultrasound contrast agents. J Cell Physiol. 2006;413–421.
   Web of Science ®Google Scholar
• Greco A, Di Benedetto A, Howard CM, et al. Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. Mol Ther. 2010;18:295–306.
   PubMed Web of Science ®Google Scholar
• Kwan JJ, Myers R, Coviello CM, et al. Ultrasound-propelled nanocups for drug delivery. Small. 2015;11:5305–5314.
   PubMed Web of Science ®Google Scholar
• Myers R, Coviello C, Erbs P, et al. Polymeric cups for cavitation-mediated delivery of oncolytic vaccinia virus. Mol Ther. 2016;24:1627–1633. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27375160
   PubMed Web of Science ®Google Scholar
• Pankhurst QA, Connolly J, Jones SK, et al. Applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys. 2003;36:R167-R181.
   Web of Science ®Google Scholar
• Hughes C, Galea-Lauri J, Farzaneh F, et al. Streptavidin paramagnetic particles provide a choice of three affinity-based capture and magnetic concentration strategies for retroviral vectors. Mol Ther. 2001;3:623–630. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11319925
   PubMed Web of Science ®Google Scholar
• Scherer F, Anton M, Schillinger U, et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther. 2002; 9102–109. Available from: www.nature.com/gt
   PubMed Web of Science ®Google Scholar
• Mah C, Fraites JTJ, Zolotukhin I, et al. Improved method of recombinant AAV2 delivery for systemic targeted gene therapy. [cited 2018 Oct 25]. Available from: http://www.idealibrary.com.
   Google Scholar
• Haim H, Steiner I, Panet A. Synchronized infection of cell cultures by magnetically controlled virus. J Virol. 2005;79:622–625. Available from : http://www.ncbi.nlm.nih.gov/pubmed/15596857
   PubMed Web of Science ®Google Scholar
• Pandori MW, Hobson DA, Sano T. Adenovirus-microbead conjugates possess enhanced infectivity: A new strategy for localized gene delivery. Virology. 2002;299:204–212.
   PubMed Web of Science ®Google Scholar
• Singh R, Kostarelos K. Designer adenoviruses for nanomedicine and nanodiagnostics. Trends Biotechnol. 2009;27:220–229.
   PubMed Web of Science ®Google Scholar
• Chan L, Nesbeth D, MacKey T, et al. Conjugation of lentivirus to paramagnetic particles via nonviral proteins allows efficient concentration and infection of primary acute myeloid leukemia cells. J Virol. 2005;79:13190–13194.
   Web of Science ®Google Scholar
• Orlando C, Castellani S, Mykhaylyk O, et al. Magnetically guided lentiviral-mediated transduction of airway epithelial cells. J Gene Med. 2010;12:747–754.
   PubMed Web of Science ®Google Scholar
• Kaikkonen MU, Viholainen JI, Närvänen A, et al. Targeting and purification of metabolically biotinylated baculovirus. Hum Gene Ther. 2008;19:589–600.
   PubMed Web of Science ®Google Scholar
• Tresilwised N, Pithayanukul P, Mykhaylyk O, et al. Boosting oncolytic adenovirus potency with magnetic nanoparticles and magnetic force. Mol Pharm. 2010;7:1069–1089. Available from: http://pubs.acs.org/doi/abs/10.1021/mp100123t
   PubMedGoogle Scholar
• Zhu H, Tong S, Bao G Magnetic control of gene delivery in vivo. 2017. Available from: https://patents.google.com/patent/US20170239370A1/en.
   Google Scholar
• Nobuto H, Sugita T, Kubo T, et al. Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet. Int J Cancer. 2004;109:627–635.
   PubMed Web of Science ®Google Scholar
• Alexiou C, Arnold W, Klein RJ, et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 2000;60(23):6641–6648.
   PubMed Web of Science ®Google Scholar
• Wadajkar AS, Bhavsar Z, Ko CY, et al. Multifunctional particles for melanoma-targeted drug delivery. Acta Biomater. 2012;8:2996–3004.
   PubMed Web of Science ®Google Scholar
• Hofmann-Amtenbrink M, von Rechenberg B, Hofmann H. Superparamagnetic nanoparticles for biomedical applications. Nano Mat for Bio Appl. 2009:119–149.
   Google Scholar
• Barnsley LC, Carugo D, Owen J, et al. Halbach arrays consisting of cubic elements optimised for high field gradients in magnetic drug targeting applications. Phys Med Biol. 2015 ;60:8303–8327. Available from: http://stacks.iop.org/0031-9155/60/i=21/a=8303?key=crossref.ac6a9a9ada743c0cc99f3d768f101c87
   PubMed Web of Science ®Google Scholar
• Willmon C, Harrington K, Kottke T, et al. Cell carriers for oncolytic viruses: fed ex for cancer therapy. Mol Ther.. 2009;17:1667–1676. Available from: https://www.sciencedirect.com/science/article/pii/S152500161632130X
   PubMed Web of Science ®Google Scholar
• Adair RA, Roulstone V, Scott KJ, et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med. 2012.
   Web of Science ®Google Scholar
• Berkeley RA, Steele LP, Mulder AA, et al. Antibody-neutralized reovirus is effective in oncolytic virotherapy. Cancer Immunol Res. 2018;6:1161–1173. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30209061
   PubMed Web of Science ®Google Scholar
• Bell J, Roy D. Cell carriers for oncolytic viruses: current challenges and future directions. Oncolytic Virother. 2013;47.
   PubMedGoogle Scholar
• Shi Y, Hu G, Su J, et al. Mesenchymal stem cells: A new strategy for immunosuppression and tissue repair. Cell Res. 2010;20:510–518.
   Web of Science ®Google Scholar
• Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science. 2006;311(80):1780–1784.
   PubMedGoogle Scholar
• Suárez-Álvarez B, Rodriguez RM, Calvanese V, et al. Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells. PLoS One. 2010;5:e10192.
   PubMed Web of Science ®Google Scholar
• Kim J, Hall RR, Lesniak MS, et al. Stem cell-based cell carrier for targeted oncolytic virotherapy: translational opportunity and open questions. Viruses. 2015;7:6200–6217.
   Web of Science ®Google Scholar